Professional Documents
Culture Documents
μάθημα11ο παθογόνα
μάθημα11ο παθογόνα
11
. .
-
2012
,
:
1.
2.
3.
:
,
, :
1. HBV
2. HCV
3. HIV 1+2
4. HTLV I/II
5. (Treponema pallidum)
Eliza
Enzyme Linked Immunosorbent Assay
Western Blot
NAT
NUCLEIC ACID TESTING SYSTEM
,
,
, ,
:
:
(NAT),
(2009)
NAT
HBV, HCV, HIV
(9)
()
(3)
:10.939.771
: 643.662
: 617,462
:
26.200
() : 618,047
1.
2.
3.
4.
5.
6.
7. ,
8.
9. .
;
:
NAT
(Polymerase Chain Reaction - PCR), Real-Time
PCR (RT-PCR) ranscription Mediated Amplification
(TMA) HIV, HBV, HCV
Polymerase Chain Reaction (PCR)
Real Time -Polymerase Chain Reaction
(RT-PCR)
Transcription Mediated Amplification (TMA)
1. Hepatitis B Virus (HBV)
1. 43nm
Dane,
,
2. 20nm,
103 - 106
3. 20nm
1. 1965
2. >2 .
350 .
3. 4 .
0.5-1.2 .
,
HBV
Symptoms
HBeAg anti-HBe
Total anti-HBc
Title
0 4 8 12 16 20 24 28 32 36 52 100
Weeks after
Exposure
HBV
HBsAg .
Anti-HBs
HBsAg
HBeAg e HBV
Anti-HBe
HBeAg HBV
Anti-HBc
HBcAg .
IgM anti-HBc IgM
HBcAg
(
)
;
HBsAg
HBsAb (anti-HBs)
HBcAb (anti-HBc)
HBsAg
HBsAb (anti-HBs)
HBcAb (anti-HBc) . .
.
HBsAg .
HBsAb (anti-HBs) .
HBcAb (anti-HBc) .
HBsAg
HBsAb (anti-HBs)
HBcAb (anti-HBc)
;
1. HBsAg:
2.
( elisa)
3.
anti-HBc,
HBeAg anti-HBe
4. anti-HBc
5. HBV-DNA
2. Hepatitis C Virus (HCV)
1. 1989 90%
-
2. ,
200 .
3. .
90%
4.
C
1. C
2. ,
3.
4. C ( 6 )
60-70%
5. (>6 ),
, 70%-80%
:
-
-
1987
-
1992
-
- 5%
- 3-5%
:
1. (10%)
2. (60%)
3.
..
4.
5.
6. (10%)
7. 5%-6% HCV (+) (14-
17% HIV)
1. 1990
anti-HCV
2. 1992
0.001% /
3. C
4. :
(RIBA, LIA) ()
HCV RNA test ,
RNA
-HCV RNA test ( ) -
( ),
;
1. Anti-HCV:
2. HCV-RNA:
3.
RIBA / LIA
4. HCV Ag
3. Human Immunodeficiency Virus (HV)
1. O HIV, AIDS
(Acquired ImmunoDeficiency Syndrome),
2.
3. ,
,
AIDS
1. HIV ,
AIDS 25 . ,
40 .
2. - ,
-HIV
3. HIV 1980
4. 2007 60 (44 & 16 )
5. : HIV-1
HIV-2.
AIDS ,
2009 600 ,
450
60 ,
519
600
30
34 (25 29 ).
1 3
33,4 .
, 71%
2008
:
.
,
. CD4+
:
CD4+
: CD4+
, ,
..
HIV-1
HIV DNA
HIV
HIV
HIV-1 p24
0 1 2 3 4 5 6 / 2 4 6 8 10
1
1. 1985
HIV-1 1992 HIV-2
2. (EIA, CMIA, ECLIA),
HIV1+2
, 20
3.
p24 ( )
;
1. Anti-HIV 1+2 (group O):
2. HIV Ag/Ab:
3. NAT-HIV:
4. HIV Western blot-LIA / HIV Ag:
4. Human T-Lymphotropic Virus (HTLV)
2. 1977
3. : HTLV I HTLV II
4. - (HTLV
I/II)
1980 1982
5. ,
HTLV-1
1.
:
- (ATLL)
HTLV-I
(HAM-TSP)
2. (
2% - 4%)
(15 20)
HTLV-2
1.
,
2.
HAM-TSP
3.
Tropical spastic paraparesis (TSP), also known as
HTLV-associated myelopathy or chronic progressive
myelopathy, is an infection of the spinal cord by Human
T-lymphotropic virus resulting in paraparesis, weakness
of the legs. As the name suggests, it is most common in
tropical regions, including the Caribbean and Africa
1.
2. : 20%
,
3. ( ,
4.
,
;
1. Anti-HTLV I/II:
2.
Treponema pallidum
.
Gram
, , ,
pH .
1.
1915
2.
3. 1930-1940:
4. '50, ,
,
, '60 '70
2010;
1.
4C
2.
3.
4 4.5
9-10
4.
1. ,
(4C)
2.
( 1.3 106 2.5
107 /ml 120
3. 48 72
4C,
4.
5.
, HIV
;
1. RPR:
,
2. TPHA,
FTAABS Elisa
phlebotomus fly
Triatomine bug
Water snail
85
102 ..
< 5 1/3
:
40%
41%
94%
1. :
4 . /
640,000
40,000
2.
&
: vCJD
/ Dengue viruses
( Babesia
) species
: Chikungunya virus
/ St Louis encephalitis virus
, Leishmania species
Plasmodium species
T. cruzi
:
Chronic wasting disease Prions,
/
HHV8,B19, H5N1, HIV variants,
,
simian foamy virus, Borrelia
/
burgdorferi, AV
(regulatory) ()
:
(watch list) S.Stramer 2009 TRANSFUSION
;
1. ;
2. ;
3. ;
Infected
Blood Recipien
t